{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:49:35Z","timestamp":1784198975354,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100020065","name":"San Antonio Medical Foundation","doi-asserted-by":"crossref","award":["SAMF 2019 Fund"],"award-info":[{"award-number":["SAMF 2019 Fund"]}],"id":[{"id":"10.13039\/100020065","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100020065","name":"San Antonio Medical Foundation","doi-asserted-by":"crossref","award":["SAMF 2019 fund"],"award-info":[{"award-number":["SAMF 2019 fund"]}],"id":[{"id":"10.13039\/100020065","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Glenda and Gary Woods Foundation","award":["Distinguished Chair in GU Oncology"],"award-info":[{"award-number":["Distinguished Chair in GU Oncology"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["8KL2 TR000118"],"award-info":[{"award-number":["8KL2 TR000118"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23"],"award-info":[{"award-number":["K23"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Mays Family Cancer Center at University of Texas Health San Antonio","award":["P30 CA054174"],"award-info":[{"award-number":["P30 CA054174"]}]},{"name":"The Roger L. and Laura D. Zeller Charitable Foundation","award":["Chair in Urologic Cancer"],"award-info":[{"award-number":["Chair in Urologic Cancer"]}]},{"DOI":"10.13039\/100006772","name":"Max and Minnie Tomerlin Voelcker Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006772","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["CA170270\/P1P2"],"award-info":[{"award-number":["CA170270\/P1P2"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009779","name":"Bladder Cancer Advocacy Network","doi-asserted-by":"publisher","award":["2016 Young Investigator Award"],"award-info":[{"award-number":["2016 Young Investigator Award"]}],"id":[{"id":"10.13039\/100009779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP170345"],"award-info":[{"award-number":["RP170345"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00262-022-03236-y","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T08:42:24Z","timestamp":1656060144000},"page":"125-136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer"],"prefix":"10.1007","volume":"72","author":[{"given":"Niannian","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijun","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreu","family":"Garcia-Vilanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Ault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan I.","family":"Moliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kizil A.","family":"Yusoof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler J.","family":"Curiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi B.","family":"Torrelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0239-1338","authenticated-orcid":false,"given":"Robert S.","family":"Svatek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"key":"3236_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3233\/BLC-150034","volume":"2","author":"NE Power","year":"2016","unstructured":"Power NE, Izawa J (2016) Comparison of guidelines on non-muscle invasive bladder cancer (EAU, CUA, AUA, NCCN, NICE). Bladder Cancer 2:27\u201336","journal-title":"Bladder Cancer"},{"key":"3236_CR2","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester RJ, Van der MA, Lamm DL (2002) Intravesical bacillus Calmette\u2013Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168:1964\u20131970","journal-title":"J Urol"},{"key":"3236_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","volume":"169","author":"A Bohle","year":"2003","unstructured":"Bohle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette\u2013Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169:90\u201395","journal-title":"J Urol"},{"key":"3236_CR4","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0022-5347(05)65966-6","volume":"166","author":"AP van der Meijden","year":"2001","unstructured":"van der Meijden AP et al (2001) Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette\u2013Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 166:476\u2013481","journal-title":"J Urol"},{"key":"3236_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","volume":"59","author":"M Babjuk","year":"2011","unstructured":"Babjuk M et al (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59:997\u20131008","journal-title":"Eur Urol"},{"key":"3236_CR6","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.5489\/cuaj.1196","volume":"3","author":"AR Zlotta","year":"2009","unstructured":"Zlotta AR, Fleshner NE, Jewett MA (2009) The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J 3:S199-205","journal-title":"Can Urol Assoc J"},{"key":"3236_CR7","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41385-019-0148-2","volume":"12","author":"JI Moliva","year":"2019","unstructured":"Moliva JI et al (2019) Selective delipidation of Mycobacterium bovis BCG enables direct pulmonary vaccination and enhances protection against Mycobacterium tuberculosis. Mucosal Immunol 12:805\u2013815","journal-title":"Mucosal Immunol"},{"key":"3236_CR8","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.4049\/jimmunol.174.8.5007","volume":"174","author":"RE Geisel","year":"2005","unstructured":"Geisel RE, Sakamoto K, Russell DG, Rhoades ER (2005) In vivo activity of released cell wall lipids of Mycobacterium bovis bacillus Calmette\u2013Guerin is due principally to trehalose mycolates. J Immunol 174:5007\u20135015","journal-title":"J Immunol"},{"key":"3236_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077930","volume":"8","author":"P Chauhan","year":"2013","unstructured":"Chauhan P et al (2013) Secretory phosphatases deficient mutant of Mycobacterium tuberculosis imparts protection at the primary site of infection in guinea pigs. PLoS ONE 8:e77930","journal-title":"PLoS ONE"},{"key":"3236_CR10","doi-asserted-by":"publisher","first-page":"e1000289","DOI":"10.1371\/journal.ppat.1000289","volume":"5","author":"C Astarie-Dequeker","year":"2009","unstructured":"Astarie-Dequeker C et al (2009) Phthiocerol dimycocerosates of M. tuberculosis participate in macrophage invasion by inducing changes in the organization of plasma membrane lipids. PLoS Pathog 5:e1000289","journal-title":"PLoS Pathog"},{"key":"3236_CR11","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.immuni.2017.08.003","volume":"47","author":"CJ Cambier","year":"2017","unstructured":"Cambier CJ, O\u2019Leary SM, O\u2019Sullivan MP, Keane J, Ramakrishnan L (2017) Phenolic glycolipid facilitates mycobacterial escape from microbicidal tissue-resident macrophages. Immunity 47:552-565e554","journal-title":"Immunity"},{"key":"3236_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nature02837","volume":"431","author":"MB Reed","year":"2004","unstructured":"Reed MB et al (2004) A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 431:84\u201387","journal-title":"Nature"},{"key":"3236_CR13","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1128\/IAI.01340-13","volume":"82","author":"TA Day","year":"2014","unstructured":"Day TA et al (2014) Mycobacterium tuberculosis strains lacking surface lipid phthiocerol dimycocerosate are susceptible to killing by an early innate host response. Infect Immun 82:5214\u20135222","journal-title":"Infect Immun"},{"key":"3236_CR14","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1021\/acschembio.6b00568","volume":"11","author":"A Arbues","year":"2016","unstructured":"Arbues A et al (2016) Trisaccharides of phenolic glycolipids confer advantages to pathogenic mycobacteria through manipulation of host-cell pattern-recognition receptors. ACS Chem Biol 11:2865\u20132875","journal-title":"ACS Chem Biol"},{"key":"3236_CR15","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1158\/2326-6066.CIR-21-0285","volume":"9","author":"N Ji","year":"2021","unstructured":"Ji N et al (2021) Gammadelta T cells support antigen-specific alphabeta T cell-mediated antitumor responses during BCG treatment for bladder cancer. Cancer Immunol Res 9:1491\u20131503","journal-title":"Cancer Immunol Res"},{"key":"3236_CR16","doi-asserted-by":"publisher","first-page":"1614857","DOI":"10.1080\/2162402X.2019.1614857","volume":"8","author":"N Ji","year":"2019","unstructured":"Ji N et al (2019) Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial. Oncoimmunology 8:1614857","journal-title":"Oncoimmunology"},{"key":"3236_CR17","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S0022-5347(17)35678-1","volume":"150","author":"TL Ratliff","year":"1993","unstructured":"Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ (1993) T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 150:1018\u20131023","journal-title":"J Urol"},{"key":"3236_CR18","doi-asserted-by":"publisher","first-page":"e001941","DOI":"10.1136\/jitc-2020-001941","volume":"9","author":"N Ji","year":"2021","unstructured":"Ji N et al (2021) Rapamycin enhances BCG-specific gammadelta T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study. J Immunother Cancer 9:e001941","journal-title":"J Immunother Cancer"},{"key":"3236_CR19","doi-asserted-by":"publisher","first-page":"36492","DOI":"10.18632\/oncotarget.26362","volume":"9","author":"N Mukherjee","year":"2018","unstructured":"Mukherjee N et al (2018) Intratumoral CD56(bright) natural killer cells are associated with improved survival in bladder cancer. Oncotarget 9:36492\u201336502","journal-title":"Oncotarget"},{"key":"3236_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.622995","volume":"12","author":"G Esteso","year":"2021","unstructured":"Esteso G et al (2021) Natural killer anti-tumor activity can be achieved by in vitro incubation with heat-killed BCG. Front Immunol 12:622995","journal-title":"Front Immunol"},{"key":"3236_CR21","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL et al (2000) Maintenance bacillus Calmette\u2013Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest oncology group study. J Urol 163:1124\u20131129","journal-title":"J Urol"},{"key":"3236_CR22","doi-asserted-by":"publisher","first-page":"29076","DOI":"10.1038\/srep29076","volume":"6","author":"V Tran","year":"2016","unstructured":"Tran V, Ahn SK, Ng M, Li M, Liu J (2016) Loss of lipid virulence factors reduces the efficacy of the BCG vaccine. Sci Rep 6:29076","journal-title":"Sci Rep"},{"key":"3236_CR23","first-page":"238","volume":"118","author":"CL Silva","year":"1985","unstructured":"Silva CL, Ekizlerian SM, Fazioli RA (1985) Role of cord factor in the modulation of infection caused by mycobacteria. Am J Pathol 118:238\u2013247","journal-title":"Am J Pathol"},{"key":"3236_CR24","doi-asserted-by":"publisher","first-page":"137ra172","DOI":"10.1126\/scitranslmed.3003586","volume":"4","author":"C Biot","year":"2012","unstructured":"Biot C et al (2012) Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med 4:137ra172","journal-title":"Sci Transl Med"},{"key":"3236_CR25","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.cub.2014.02.053","volume":"24","author":"Y Kawai","year":"2014","unstructured":"Kawai Y, Mercier R, Errington J (2014) Bacterial cell morphogenesis does not require a preexisting template structure. Curr Biol 24:863\u2013867","journal-title":"Curr Biol"},{"key":"3236_CR26","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/S0022-5347(05)66410-5","volume":"165","author":"C Durek","year":"2001","unstructured":"Durek C et al (2001) The fate of bacillus Calmette\u2013Guerin after intravesical instillation. J Urol 165:1765\u20131768","journal-title":"J Urol"},{"key":"3236_CR27","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/s41598-017-01501-0","volume":"7","author":"M Jankute","year":"2017","unstructured":"Jankute M et al (2017) The role of hydrophobicity in tuberculosis evolution and pathogenicity. Sci Rep 7:1315","journal-title":"Sci Rep"},{"key":"3236_CR28","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.3389\/fimmu.2019.02909","volume":"10","author":"A Garcia-Vilanova","year":"2019","unstructured":"Garcia-Vilanova A, Chan J, Torrelles JB (2019) Underestimated manipulative roles of mycobacterium tuberculosis cell envelope glycolipids during infection. Front Immunol 10:2909","journal-title":"Front Immunol"},{"issue":"Pt 7","key":"3236_CR29","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1099\/0022-1317-78-7-1597","volume":"78","author":"MM Hoq","year":"1997","unstructured":"Hoq MM et al (1997) Role of gamma delta TCR+ lymphocytes in the augmented resistance of trehalose 6,6\u2019-dimycolate-treated mice to influenza virus infection. J Gen Virol 78(Pt 7):1597\u20131603","journal-title":"J Gen Virol"},{"key":"3236_CR30","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.juro.2017.01.086","volume":"198","author":"BE Boehm","year":"2017","unstructured":"Boehm BE et al (2017) Efficacy of bacillus Calmette\u2013Guerin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis. J Urol 198:503\u2013510","journal-title":"J Urol"},{"key":"3236_CR31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/iju.13538","volume":"25","author":"J Miyazaki","year":"2018","unstructured":"Miyazaki J, Onozawa M, Takaoka E, Yano I (2018) Bacillus Calmette\u2013Guerin strain differences as the basis for immunotherapies against bladder cancer. Int J Urol 25:405\u2013413","journal-title":"Int J Urol"},{"key":"3236_CR32","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12894-020-00766-4","volume":"20","author":"D Koguchi","year":"2020","unstructured":"Koguchi D et al (2020) Impact of maintenance therapy using a half dose of the bacillus Calmette-Guerin Tokyo strain on recurrence of intermediate and high-risk nonmuscle invasive bladder cancer: a retrospective single-center study. BMC Urol 20:194","journal-title":"BMC Urol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03236-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03236-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03236-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T12:05:05Z","timestamp":1672833905000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03236-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["3236"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03236-y","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,24]]},"assertion":[{"value":"6 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies related to this manuscript were conducted abided by research ethics and approved IACUC (#20120040AR) for animal or clinical sample use (IRB protocol HSC2012-159H). All authors have consent for publishing the data from these studies. Corresponding author R.S.S. discloses other roles as Consultant for FerGene and Clinical Research Support for JBL (SWOG), FKD and Decipher Biosciences. All other authors disclose no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}